bioAffinity Technologies (BIAF) Revenue (2022 - 2026)

bioAffinity Technologies has disclosed Revenue across 5 years of filings, most recently posting $1.4 million for Q1 2026.

• In Q1 2026, Revenue fell 27.09% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $5.7 million (down 35.75% YoY), while the FY2025 annual figure was $6.2 million, down 34.18% from the prior year.
• Revenue declined to $1.4 million in Q1 2026, from $1.6 million in the prior quarter.
• Over the last five years, Revenue for BIAF reached as high as $2.4 million in Q1 2024 and fell as low as $921.0 in Q1 2023.
• The 5-year median for Revenue is $1.4 million (2025), against an average of $1.2 million.
• Annual changes were most pronounced in 2024 — Revenue soared 261180.24% — and 2025, when it sank 47.05%.
• A 5-year view of Revenue shows it stood at $2346.0 in 2022, then surged by 94245.95% to $2.2 million in 2023, then decreased by 0.26% to $2.2 million in 2024, then declined by 27.85% to $1.6 million in 2025, then declined by 15.15% to $1.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $1.4 million, $1.6 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.